A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma or Melanoma
Memorial Sloan Kettering Cancer Center
20 participants
Sep 28, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05562791